Alfasigma S.P.A.
Records under this name other than the patents Alfasigma S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 82 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,464,814 | Topical Composition for Use in the Treatment of Inflammatory Bowel Disease Lapsed on the fee record Ended Oct 11, 2026 · High confidence | Lapsed on the fee record | Ended Oct 11, 2026 | High confidence |
| US 11,433,043 | Compounds Useful for Increasing Neurogenesis in Neural Tissue Lapsed on the fee record Ended Sep 6, 2026 · High confidence | Lapsed on the fee record | Ended Sep 6, 2026 | High confidence |
| US 7,375,114 | Quinolinone-Carboxamide Compounds as 5-HT4 Receptor Agonists Term ended Ended no later than Jul 27, 2026 · Medium confidence | Term ended | Ended no later than Jul 27, 2026 | Medium confidence |
| US 10,285,944 | Gastroresistant pharmaceutical formulations containing rifaximin Term ended Term ended Jul 16, 2026 · From the USPTO record | Term ended | Term ended Jul 16, 2026 | From the USPTO record |
| US 8,758,835 | Composition useful for the prevention or reduction of the progression of prostate cancer Lapsed on the fee record Ended Jun 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | From the USPTO record |
| US 7,728,006 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists Term ended Term ended Jun 12, 2026 · From the USPTO record | Term ended | Term ended Jun 12, 2026 | From the USPTO record |
| US 8,748,447 | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect Lapsed on the fee record Ended Jun 10, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 10, 2026 | From the USPTO record |
| US 8,748,449 | Use of polyols to obtain stable polymorphous forms of rifaximin Lapsed on the fee record Ended Jun 10, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 10, 2026 | From the USPTO record |
| US 9,126,994 | Crystalline form of a quinolinone-carboxamide compound Term ended Term ended Apr 5, 2026 · From the USPTO record | Term ended | Term ended Apr 5, 2026 | From the USPTO record |
| US 9,402,840 | Crystalline form of a quinolinone-carboxamide compound Term ended Term ended Apr 5, 2026 · From the USPTO record | Term ended | Term ended Apr 5, 2026 | From the USPTO record |